Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells

Pediatric Allergy and Immunology

Volumn 21, Issue 2 PART 1, 2010, Pages 345-352

  Chu, Yu Te ^a   Chang, Tai Tsung ^a,b   Jong, Yuh Jyh ^a,b   Kuo, Po Lin ^c   Lee, Hsi Ming ^d   Lee, Min Sheng ^a   Chang, Hui Wen ^a   Hung, Chih Hsing ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

2 agonist; BEAS 2B; Bronchial epithelium; Eotaxin 1; Formoterol; Salmeterol

Indexed keywords

EOTAXIN; FORMOTEROL; FORSKOLIN; INTERLEUKIN 4; SALMETEROL; STAT6 PROTEIN;

ARTICLE; ASTHMA; BRONCHUS MUCOSA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TREATMENT OUTCOME; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; BRONCHI; CELL LINE; CHEMOKINE CCL11; ETHANOLAMINES; FORSKOLIN; HUMANS; INTERLEUKIN-4; PROPANOLAMINES; RESPIRATORY MUCOSA; STAT6 TRANSCRIPTION FACTOR;

EID: 77950287667     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2009.00906.x     Document Type: Article

References (32)

1. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996 : 9 : 1684 1688.
2. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994 : 7 : 103 107.
3. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997 : 10 : 2484 2489.
4. Ullman A, Bergendal A, Linden A, Waldeck B, Skoogh BE, Lofdahl CG. Onset of action and duration of effect of formoterol and salmeterol compared to salbutamol in isolated guinea pig trachea with or without epithelium. Allergy 1992 : 47 : 384 387.
5. Nials AT, Ball DI, Butchers PR, et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994 : 251 : 127 135.
6. Hung CH, Chu YT, Hua YM, et al. Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells. Eur Respir J 2008 : 31 : 1313 1321.
7. Nie M, Knox AJ, Pang L. beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 2005 : 175 : 478 486.
8. Nie M, Corbett L, Knox AJ, Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J Biol Chem 2005 : 280 : 2550 2561.
9. Miyabayashi K, Maruyama M, Yamada T, et al. Isoproterenol suppresses cytokine-induced RANTES secretion in human lung epithelial cells through the inhibition of c-jun N-terminal kinase pathway. Biochem Biophys Res Commun 2006 : 350 : 753 761.
10. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004 : 10 : 493 499.
11. Eum SY, Maghni K, Hamid Q, et al. Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: role of eosinophils, IL-5, eotaxin, and IL-13. J Allergy Clin Immunol 2003 : 111 : 1049 1061.
12. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997 : 277 : 2005 2007.
13. Ko FW, Lau CY, Leung TF, et al. Exhaled breath condensate levels of eotaxin and macrophage-derived chemokine in stable adult asthma patients. Clin Exp Allergy 2006 : 36 : 44 51.
14. Park SW, Kim do J, Chang HS, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. Int Arch Allergy Immunol 2003 : 131 : 283 290.
15. Stelmach I, Majak P, Grzelewski T, et al. The ECP/Eo count ratio in children with asthma. J Asthma 2004 : 41 : 539 546.
16. Rojas-Ramos E, Avalos AF, Perez-Fernandez L, Cuevas-Schacht F, Valencia-Maqueda E, Teran LM. Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4, and eotaxins-1 and -2 in childhood asthma. Eur Respir J 2003 : 22 : 310 316.
17. Chu YT, Chiang W, Wang TN, Hung CH, Jong YJ, Wu JR. Changes in serum eotaxin and eosinophil cationic protein levels, and eosinophil count during treatment of childhood asthma. J Microbiol Immunol Infect 2007 : 40 : 162 167.
18. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996 : 97 : 604 612.
19. Li D, Wang D, Griffiths-Johnson DA, et al. Eotaxin protein and gene expression in guinea-pig lungs: constitutive expression and upregulation after allergen challenge. Eur Respir J 1997 : 10 : 1946 1954.
20. Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997 : 7 : 836 843.
21. Hung CH, Li CY, Lai YS, Hsu PC, Hua YM, Yang KD. Discrepant clinical responses and blood chemokine profiles between two non-steroidal anti-inflammatory medications for children with mild persistent asthma. Pediatr Allergy Immunol 2005 : 16 : 306 309.
22. Hung CH, Li CY, Hua YM, Chen CJ, Yang KD, Jong YJ. Effects of leukotriene receptor antagonists on monocyte chemotaxis, p38 and cytoplasmic calcium. Pediatr Allergy Immunol 2006 : 17 : 250 258.
23. Hung CH, Suen JL, Hua YM, et al. Suppressive effects of ketotifen on Th1- and Th2-related chemokines of monocytes. Pediatr Allergy Immunol 2007 : 18 : 378 384.
24. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999 : 21 : 291 295.
25. Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997 : 99 : 1767 1773.
26. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 2005 : 175 : 5341 5350.
27. Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 2006 : 317 : 244 250.
28. Scola AM, Chong LK, Suvarna SK, Chess-Williams R, Peachell PT. Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol. Br J Pharmacol 2004 : 141 : 163 171.
29. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001 : 17 : 1070 1077.
30. O'Byrne P, Bateman ED, Bousquet J, et al. The global initiative for asthma. 2007 : 34 5.
31. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006 : 117 : 18 24.
32. Weinberger MH. Potential benefit of combination therapy with diuretics and beta blockers having intrinsic sympathomimetic activity. Eur Heart J 1990 : 11 : 560 565.